Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.71 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.71 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.65 |
| ▸ | LMNA | P02545 | 1/20 | 0.65 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.65 |
| ▸ | DHODH | Q02127 | 5/20 | 0.61 |
| ▸ | NPC1 | O15118 | 2/20 | 0.60 |
| ▸ | RAB9A | P51151 | 2/20 | 0.60 |
| ▸ | TACR3 | P29371 | 1/20 | 0.59 |
| ▸ | POLB | P06746 | 2/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.56 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.56 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.56 |
| ▸ | ESR1 | P03372 | 1/20 | 0.56 |
| ▸ | TP53 | P04637 | 1/20 | 0.56 |
| ▸ | GLA | P06280 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | HPGD | P15428 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31620661 | 1.00 | MEN1 (0.71) | MEN1KMT2AKDM4ESMN1; SMN2LMNA | |
| SCHEMBL13957848 | 0.88 | TACR3 (0.57) | MEN1KMT2AKDM4ESMN1; SMN2LMNA | |
| SCHEMBL31490593 | 0.87 | DHODH (0.69) | MEN1KMT2AKDM4ESMN1; SMN2LMNA | |
| SCHEMBL8324531 | 0.86 | MEN1 (0.77) | MEN1KMT2AKDM4ESMN1; SMN2LMNA | |
| SCHEMBL31490595 | 0.85 | DHODH (0.66) | MEN1KMT2AKDM4ESMN1; SMN2LMNA | |
| SCHEMBL18746 | 0.84 | KDM4E (0.83) | MEN1KMT2AKDM4ESMN1; SMN2LMNA | |
| SCHEMBL29359819 | 0.84 | KDM4E (0.83) | MEN1KMT2AKDM4ESMN1; SMN2LMNA | |
| SCHEMBL19520848 | 0.83 | MEN1 (0.73) | MEN1KMT2AKDM4ESMN1; SMN2LMNA | |
| Potassium SCHEMBL93448 | 0.82 | KDM4E (0.80) | MEN1KMT2AKDM4ESMN1; SMN2LMNA | |
| SCHEMBL374556 | 0.82 | KDM4E (0.80) | MEN1KMT2AKDM4ESMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2325181-B1 | STAT3 INHIBITOR CONTAINING QUINOLINECARBOXAMIDE DERIVATIVE AS ACTIVE INGREDIENT | GENERAL INCORPORATED ASS PHARMA VALLEY PROJECT SUPPORTING ORGANIZATION (JP) | 2017-03-29 | — | — | EP | disclosed |
| CN-102099352-B | STAT3 inhibitor containing quinolinecarboxamide derivative as active ingredient | PHARMA IP GENERAL INC ASS | 2014-02-26 | — | — | CN | disclosed |
| US-8466290-B2 | STAT3 inhibitor containing quinolinecarboxamide derivative as active ingredient | PHARMA IP GENERAL INCORPORATED ASSOCIATION (JP) | 2013-06-18 | — | — | US | disclosed |
| US-20110172429-A1 | STAT3 INHIBITOR CONTAINING QUINOLINECARBOXAMIDE DERIVATIVE AS ACTIVE INGREDIENT | PHARMA IP GENERAL INCORPORATED ASSOCIATION (JP) | 2011-07-14 | — | — | US | disclosed |
| CN-102099352-A | STAT3 inhibitor containing quinolinecarboxamide derivative as active ingredient | PHARMA IP GENERAL INC ASS | 2011-06-15 | — | — | CN | disclosed |
| EP-2325181-A1 | STAT3 INHIBITOR CONTAINING QUINOLINECARBOXAMIDE DERIVATIVE AS ACTIVE INGREDIENT | Pharma Ip General Incorporated Association (JP) | 2011-05-25 | — | — | EP | disclosed |
| US-4711890-A | TREATMENT OF ANXIETY STATES OR OF PULMONARY, RENAL, CIRCULATORY OF CARDIOVASCULAR DISORDERS | RHONE-POULENC SANTE (FR) | 1987-12-08 | — | — | US | disclosed |
| US-4684652-A | TREATING ANXIETY OR CARDIOVASCULAR DISORDERS | RHONE-POULENC SANTE (FR) | 1987-08-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110172429-A1 | STAT3 INHIBITOR CONTAINING QUINOLINECARBOXAMIDE DERIVATIVE AS ACTIVE INGREDIENT | STAT3, STAT4, STAT5B | MEN1 4247/4885KMT2A 255/4885KDM4E 532/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.